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231Abstracts
CLUSIONS: Consistent with survey ﬁndings, prostate
cancer patients were signiﬁcantly more likely to be diag-
nosed with depression compared to cancer free indi-
viduals. Cancer patients with depression accumulated
substantially higher expenditures than those without
depression. Improved depression screening and treatment
may lead to reduced healthcare costs and better quality-
of-life for cancer patients.
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OBJECTIVES: Variations in disease treatment and 
costs for US Colorectal Cancer (CRC) patients may be
explained by factors beyond characteristics of disease and
treatment. Patient characteristics may impact CRC treat-
ment and costs. The aim of the study is to investigate
whether patient characteristics such as payor, gender, and
age impact inpatient health care resource use and costs
for US CRC patients. METHODS: Primary study end-
points—hospital length of stay (LOS) and average daily
charges (ADC) among CRC patients were examined using
data from Health Care Utilization Project (HCUP)
Nationwide Inpatient Sample. Hospital discharges from
1993–1999 with principal discharge diagnosis of CRC
were included. All charges were expressed in 2000 US
dollars. Ordinary least square (OLS) models with log
transformation of LOS and ADC were developed. Covari-
ates were: gender, primary payor, age, year, and teaching
hospital. Disease-speciﬁc risk factors were also included
as potential confounders. RESULTS: We identiﬁed
213,875 CRC discharges. The mean LOS and ADC for
the reference groups were: 9.9 days and $2878 for male;
8.5 days and $2944 for HMO; 9.9 days and $2875 for
patients aged £54 years; 9.9 days and $2775 for non-
teaching hospital; and 11.5 days and $2589 for the year
1993. Semi-log OLS models, after controlling for other
covariates, indicated that female, Medicare, Medicaid,
self-pay, older people, and teaching hospital were associ-
ated with longer LOS (P < 0.0001); female, Medicaid,
Medicare, self-pay were associated with lower ADC,
while teaching hospital was associated with higher ADC
(P < 0.0001). Adjusted LOS declined at an annual rate of
3.7%, while ADC grew annually at 2.5%. CONCLU-
SIONS: Patient characteristics contributed to the varia-
tion of inpatient resource use for CRC patients. This
association provides health care policy decision-makers
information regarding treatment practices. Further re-
search should examine whether the association is ob-
served for other tumors and disease areas.
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OBJECTIVE: To determine health care resource utiliza-
tion and costs over ﬁve years among Veterans Adminis-
tration (VA) patients with cancer of the sigmoid colon.
METHODS: This retrospective study was limited to
veteran patients in New Mexico diagnosed between 1995
and 2000. Demographic information and data for out-
patient medications, imaging, chemotherapy, hospitaliza-
tions, number of clinic visits, and number of physician
visits were collected using VA databases. Costs applied
for all services other than outpatient medications and
chemotherapy were based upon 2001 Medicaid reim-
bursement values. Drug costs were based upon 2001 VA
prices. RESULTS: There were 46 total patients (45 male)
identiﬁed and data for years 2–5 was available for 35, 21,
19, and 11 patients respectively. The mean age was 72
years (+/-7.78), with a range of 49–87. Twenty-two
(48%) patients were in Stage 3 or 4, with lymph node
involvement and/or metastases, at ﬁrst diagnosis. The
mean resource utilization per patient was greatest in year
1 ($8,269 ± 7,434), followed by year 2 ($2,792 ± 4,935),
then year 5 ($1,496 ± 2,759). The top three cost drivers
for years 1 through 3 were hospitalization, chemother-
apy, and clinic visits versus hospitalization, imaging, and
clinic visits for years 4 and 5. The mean costs for treat-
ing Stage 3 or 4 patients were signiﬁcantly higher (p <
0.05) for years 1 and 5, year 1: ($10,959 +/- 9,481 versus
$5,867 +/- 3,641) and year 5: ($6,117 +/- 4,688 versus
$470 +/- 495). CONCLUSION: This initial economic
analysis helps identify costs and costs drivers in the treat-
ment of cancer of the sigmoid colon. The study can serve
as a model for data collection processes in the VA regard-
ing direct medical costs of cancer of the sigmoid colon.
With additional data, pharmacoeconomic modeling
research regarding prevention strategies and/or screening
methods could be performed.
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OBJECTIVES: Letrozole (Femara) offers increased life
expectancy with tolerable side effects for the management
of advanced breast cancer. The budget and population
